Asset Details
Do you wish to reserve the book?
Pharmacological and behavioral profile of N-(3R)-1-azabicyclo2.2.2oct-3-yl-6-chinolincarboxamide (EVP-5141), a novel alpha7 nicotinic acetylcholine receptor agonist/serotonin 5-HT^sub 3^ receptor antagonist
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacological and behavioral profile of N-(3R)-1-azabicyclo2.2.2oct-3-yl-6-chinolincarboxamide (EVP-5141), a novel alpha7 nicotinic acetylcholine receptor agonist/serotonin 5-HT^sub 3^ receptor antagonist
Do you wish to request the book?
Pharmacological and behavioral profile of N-(3R)-1-azabicyclo2.2.2oct-3-yl-6-chinolincarboxamide (EVP-5141), a novel alpha7 nicotinic acetylcholine receptor agonist/serotonin 5-HT^sub 3^ receptor antagonist
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacological and behavioral profile of N-(3R)-1-azabicyclo2.2.2oct-3-yl-6-chinolincarboxamide (EVP-5141), a novel alpha7 nicotinic acetylcholine receptor agonist/serotonin 5-HT^sub 3^ receptor antagonist
2013
Overview
Agonists of [alpha]7 nicotinic acetylcholine receptors (nAChRs) may have therapeutic potential for the treatment of cognitive deficits. This study describes the in vitro pharmacology of the novel [alpha]7 nAChR agonist/serotonin 5-HT^sub 3^ receptor (5-HT^sub 3^R) antagonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141) and its behavioral effects. EVP-5141 bound to [alpha]7 nAChRs in rat brain membranes (K ^sub i^=270 nM) and to recombinant human serotonin 5-HT^sub 3^Rs (K ^sub i^=880 nM) but had low affinity for [alpha]4[beta]2 nAChRs (K ^sub i^>100 [mu]M). EVP-5141 was a potent agonist at recombinant rat and human [alpha]7 nAChRs expressed in Xenopus oocytes. EVP-5141 acted as 5-HT^sub 3^R antagonist but did not block [alpha]3[beta]4, [alpha]4[beta]2, and muscle nAChRs. Rats trained to discriminate nicotine from vehicle did not generalize to EVP-5141 (0.3-30 mg kg^sup -1^, p.o.), suggesting that the nicotine cue is not mediated by the [alpha]7 nAChR and that EVP-5141 may not share the abuse liability of nicotine. EVP-5141 (0.3-3 mg kg^sup -1^) improved performance in the rat social recognition test. EVP-5141 (0.3 mg kg^sup -1^, p.o.) ameliorated scopolamine-induced retention deficits in the passive avoidance task in rats. EVP-5141 (1 mg kg^sup -1^, i.p.) improved spatial working memory of aged (26- to 32-month-old) rats in a water maze repeated acquisition task. In addition, EVP-5141 improved both object and social recognition memory in mice (0.3 mg kg^sup -1^, p.o.). EVP-5141 improved performance in several learning and memory tests in both rats and mice, supporting the hypothesis that [alpha]7 nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits in Alzheimer's disease or schizophrenia.[PUBLICATION ABSTRACT]
Publisher
Springer Nature B.V
Subject
